pharma · Thyroid eye disease · Thyroid Eye Disease · VRDN
Viridian Pharma
Viridian Pharma Ltd
Viridipharm is a pharma organization headquartered in Elmwood Park, USA. It trades on NYSE under ticker VRDN. Primary therapeutic focus areas include Thyroid eye disease, Thyroid Eye Disease, Thyroid eye disease (TED), T
200 Market Street, ELMWOOD PARK, NJ 07407, US HQ
2017 Founded
2 Employees
Public company Type
VRDN · NYSE Ticker
Company details
- Status
- Public
- HQ
- 200 Market Street, ELMWOOD PARK, NJ 07407, US
- Founded
- 2017
- Employees
- 2
- Programs
- 13
- Drugs
- 11
- Patents
- 3
VRDN-001 Phase 3 Cohort (THRIVE)
Phase 3 · small molecule · Thyroid Eye Disease
VRDN-001 Phase 3 Cohort (THRIVE) for Thyroid Eye Disease is a Phase 3 program (small_molecule) at Viridian Pharma Ltd with 1 ClinicalTrials.gov record(s).
Internal code VRDN-001-101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Viridian Pharma Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Thyroid Eye Disease
- Status
- completed
- Trials
- 1